Company Introduction

Formosa Pharmaceuticals, a subsidiary of globally-respected API provider, Formosa Laboratories (TWSE 4746), is a discovery and late-preclinical stage biopharmaceutical company with focus in the indications of ophthalmology, oncology, and anti-infectives.

In August, 2017, Formosa Pharmaceuticals completed the acquisition of Activus Pharmaceuticals (Japan). The acquisition affords Formosa Pharmaceuticals the Activus Pure Nanoparticle Technology Platform (APNT), and two late-stage preclinical assets in the area of ophthalmology. Of these ophthalmology candidates, APP13007, is nearing completion of Phase II clinical trials for post-ocular surgery pain and inflammation in the United States.

Along with global strategic partners, Formosa Pharmaceuticals has assembled a vibrant pipeline of diverse assets. Each opportunity has a different risk profile and enjoys a unique advantage with respect to the company’s resources, infrastructure, and network.

Formosa Pharmaceuticals continues to seek additional valued partnerships to complement its existing pipeline and platform technologies.

 

Business Strategy & Core Competence

Formosa Pharma’s foundation is predicated on medicinal chemistry expertise led by Dr. C.Y. Cheng and Dr. Erick Co, with more than 50 years of combined academic and industrial experience in new drug discovery. Formosa Pharma is also responsible for fund-raising, scouting and in-licensing of promising development candidates, project management and coordination amongst our partners.

Our 2017 acquisition of Activus Pharma, Japan, has afforded us the APNT platform, a unique nanoparticle technology for organic molecules of low water-solubility, and two nanoparticle ophthalmology drugs with 505(b)(2) opportunities. The APNT technology will continue to provide opportunities for in-house development or co-development with other inventors of small molecule drugs exhibiting low water solubility.

Formosa Pharma’s alliance with AimMax Therapeutics in the US allows us to have access to an experienced team covering all essential functional areas capable of carrying out necessary development work to take early stage molecules efficiently through enhanced research, IND-enabling development into IND submission, IND approval and subsequent phase 1 and 2 trials, with a strong representation in the US, the most important market for new medicines. We also work together to seek out-licensing opportunity at a proper timing and commercialization in the global market.

 

Leadership

Senior Management
Dr. Chen-Yu Cheng, Ph.D., Chairman and President
Dr. CY Cheng founded Formosa Laboratories, Inc. in 1996, and Formosa Pharmaceuticals in 2010. He received his Ph.D. degree in Medicinal Chemistry from University of California, San Francisco, and conducted postdoctoral research at MIT. He has over 35 years’ pharmaceutical industrial experience including at DuPont in Delaware, USA. Dr. Cheng was also the Professor in the College of Pharmacy at National Taiwan University.
Dr. Erick Co, Ph.D., Chief Executive Officer
Dr. Erick Co has over 20 years’ drug discovery experience leading to the invention of 6 preclinical and clinical drug candidates. He received his B.S. degree in Chemistry from the California Institute of Technology, and a Ph.D. in Synthetic Organic Chemistry from University of California, Los Angeles. Trained as a medicinal chemist in leading biotech and pharma companies such as Exelixis and Takeda, where he contributed to several clinical phase candidates, Erick transitioned into managerial roles at Nitto Denko and ScinoPharm Taiwan. He serves as Chief Executive Officer for Formosa Pharmaceuticals and oversees its wholly-owned subsidiary, Activus Pharmaceuticals, in Japan.
Dr. YuChi Chen, Ph.D., Director of Nanotechnology
Dr. Chen has over 15 years’ industry and academia experience in Food and Cosmetic sciences. Prior to joining Formosa Pharmaceuticals, he was a Professor at Vanung University in Taoyuan, Taiwan where he served as the Vice Chairman. Dr. Chen’s educational training includes a postdoctoral appointment at the National Health Research Institutes of Taiwan, and a Ph.D. in Food and Nutritional Sciences at the University of Shizuoka, Japan. Dr. Chen now heads the Nanotechnology division of Formosa Pharmaceuticals, developing APP13007, APP13002, and directing new research to expand the scope of the APNT formulation platform.
Ms. Kate Tsan, M.S., Manager, Project Management
Ms. Tsan earned her B.S. in Zoology at National Taiwan University and M.S. in Toxicology at the University of Michigan. Upon returning to Taiwan she worked at several prominent R&D outsourcing and clinical management firms in Taipei. Kate now leads the Project Management team at Formosa Pharmaceuticals, overseeing the progress and development of all programs.
 
Board of Directors and Supervisors
Dr. Chen-Yu Cheng, Ph.D., Board Chairman
Dr. CY Cheng founded Formosa Laboratories, Inc. in 1996, and Formosa Pharmaceuticals in 2010. He received his Ph.D. degree in Medicinal Chemistry from University of California, San Francisco, and conducted postdoctoral research at MIT. He has over 35 years’ pharmaceutical industrial experience including at DuPont in Delaware, USA. Dr. Cheng was also the Professor in the College of Pharmacy at National Taiwan University.
Dr. Hong-Jen Chang, Board Director
Dr. Hong-Jen Chang currently serves as Chairman and CEO of YFY Biotech Management Company. Prior to joining the YFY Group, Dr. Chang had extensive experience in health care. During his 16-year service with the government, he held several key positions in the Taiwanese Ministry of Health and Welfare and served as President & CEO of Bureau of National Health Insurance (BNHI) and Director General of Center of Disease Control.
Dr. Chang received his medical degree from National Yang-Ming Medical College, he also holds Master degree in Public Health from National Taiwan University, and Master of Science in Health Policy and Management from Harvard School of Public Health.
Dr. Jo Shen, Board Director
Dr. Jo Shen is the Co-Founder for ScinoPharm Taiwan, Ltd., and served as its Chief Executive Officer and President for 17 years. Dr. Shen has more than 40 years of experience in the industry regarding international pharmaceutical executive. Prior to ScinoPharm, she worked with Syntex and Monsanto. Dr. Shen holds a Ph.D. in Physical Chemistry from Lehigh University, a M.S. in Inorganic Chemistry from the University of Iowa and a B.S. in Chemical Engineering from National Taiwan University. Dr. Shen is a Venture Partner at Vivo Capital, LLC since 2016.
Dr. Laurene Wang, Board Director
Dr. Laurene Wang has over 30 years of hands-on, management and leadership experience in the multidisciplinary areas of pharmaceutical research, development and regulations. She received a PhD degree in Clinical Pharmacology and Pharmaceutical Chemistry, University of California, San Francisco. She worked for Big Pharma, including Burroughs Wellcome, Glaxo Wellcome / GlaxoSmithKline and start-ups, Triangle Pharmaceuticals / Gilead Sciences, DarPharma, international clinical CROs and regulatory consulting firms. She is a reviewer at the US FDA and the Clinical Center of the NIH.
Dr. Che-Ming Teng, Board Director
Dr. Che-Ming Teng is Director and Professor Emeritus at College of Pharmacy and Director of Branch Office of Research and Development of National Taiwan University and visiting professor at Taipei Medical University. Dr. Teng also serves as Chief Investigator at National Research Program for Biopharmaceuticals, Taiwan and Minister without Portfolio to the Executive Yuan of Taiwan.
Dr. Weng-Foung Huang, Board Director
Dr. Weng-Foung Huang is Adjunct Professor at Institute of Health and Welfare Policy at National Yang-Ming University. He also serves as Board Director at Taiwan Bio Industry Organization and Board Director at Development Center for Biotechnology. Dr. Huang was Chairman of Pharmacist Disciplinary Committee in Ministry of Health and Welfare and Director General of National Laboratories of Foods and Drugs in Department of Health of Taiwan.
Mr. Rick Chiang, Board Director
Mr. Chiang founded Blackmarble Capital Management in 2015 after a distinguished tenure as CEO of H&Q Taiwan. In addition to serving as Chairman of Blackmarble, where he is responsible for the firm’s overall operations and fund management, Mr. Chiang is also the Director of the Taiwan Private Equity & Venture Capital Association. Mr. Chiang has a successful track record of investing in various industries ranging from IT, semiconductor, optoelectronics, communications, passive components, electro mechanics, automobile components, pharmaceuticals and computer peripherals /accessories. His expertise covers areas such as company management and restructurings, industry strategic alliances, M&A and finance. Besides, he is also familiar with the Asia Pacific and Taiwan capital markets. Mr. Chiang obtained both his MBA degree and Bachelor’s Degree of Business Administration from National Chung Hsing University in 1989 and 1987 respectively. He is also a certified securities analyst from the Securities and Futures institute since 1993.
Mr. William Chung, Supervisor
Mr. William Chung has more than 10 years in venture investment experience in the life science and biotech/pharmaceutical industry. Currently he serves as Managing Director in H&Q Taiwan, and H&Q Asia Pacific, focusing on investment in Pharmaceutical and Healthcare sectors. He is actively involved in portfolio management and works with portfolio companies closely in providing operational and business development support. Mr. Chung received his B.S. and M.S. in Agricultural Chemistry from National Taiwan University. In addition, he studied for four years in the PhD program at Imperial College London and University of Cambridge, UK.
Mr. Mark Hsieh, Supervisor
Mr. Mark Hsieh is the Chairman of Synmax Biochemical Co., Ltd, a company with particular focus on enzymatic applications, fermentation and specialty chemicals. He is also the Chairman of the non-profit Food Industry Research and Development Institute (FIRDI) in Taiwan which also operates one of the largest microbial depositories in Asia. Mr. Hsieh graduated from Columbia University with MA in International Affairs and was an Eisenhower Fellow in 2014. He is also a Director of the Chinese National Association of Industries (CNFI), the largest industrial Association in Taiwan.
ABOUT
PIPELINE
TECHNOLOGY
PARTNERS
CONTACT
 
Formosa Pharmaceuticals, Inc.
8F-6, No. 57, Fuxing N. Rd., Songshan Dist., Taipei City 105, Taiwan
+886-2-2755-7659
 
© 2018 Formosa Pharmaceuticals, Inc. All Rights Reserved.